ReviewAAPS PharmSciTech2025
Advances in Pharmaceutical Cocrystals and Nano-Cocrystals: Strategies for Enhancing Solubility and Translating to Clinical Use.
Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor oral bioavailability in most modern pharmaceuticals is primarily caused by poor aqueous solubility. Most NCEs (New Chemical Entities) and nearly 40% of drugs on the market fall into either Biopharmaceutical Classification System (BCS) class II or IV, both characterized by very poor aqueous solubility. This leads to a higher demand for techniques that improve solubility in water-based media. This study aims to compile and present a comprehensive and detailed assessment of cocrystals and nano-cocrystals. It emphasizes the importance of in-depth research into nano-cocrystals to gather more raw data, which will support the eventual translation of nano-cocrystals into clinical use and market approval. Cocrystal technology has been used to enhance various physicochemical parameters, including stability, solubility, and bioavailability. Nano-cocrystallization is a new emerging technique that combines the benefits of cocrystallization with nanosizing, resulting in cocrystals with improved physicochemical properties and increased surface area due to nanoscale particles. These methods not only enhance aqueous solubility but have also been shown to directly increase the dissolution rate and improve the dissolution profile of drug substances. A literature review was conducted using PubMed, Scopus, and patent databases. Cocrystals and multicomponent systems are discussed with an emphasis on their crystal structure, types and nature of bonds formed, and any significant variations or special characteristics are highlighted. This thorough review offers an overview of cocrystals and nano-cocrystals, outlining the cocrystallization process and various methods for formulation and characterization. It also covers the selection process for coformers, including new computational, AI, and machine learning techniques for screening. The review introduces nano-cocrystals, describing their synthesis methods and benefits. It discusses polymorphism in both cocrystals and nano-cocrystals, and compares cocrystals as a way to improve solubility. Additionally, it evaluates their different applications and clinical outcomes. The discussion points out that the limited research on nano-cocrystals hinders their translation into industrial and clinical use. In contrast, cocrystals, despite some barriers, have achieved notable commercial success.
Indexed as
Identifiers
41044456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.